Alendronate reduces the excretion of risk factors for calcium phosphate stone formation in postmenopausal women with osteoporosis.

Potential approach with BPs may be associated with thiazide diuretics or indapamide in the management of post-menopausal women with HC and associated bone loss.

Studies on the larger sample size are needed to demonstrate the efficacy on the fracture outcome.

ALN not only improves BMD and osteoporosis, but also reduces the risk of calcium phosphate stone formation in postmenopausal women.